- Home
- VRDN vs MMI Comparison
VRDN vs MMI Comparison
Compare VRDN & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- MMI
- Stock Information
- Founded
- VRDN 2006
- MMI 1971
- Country
- VRDN United States
- MMI United States
- Employees
- VRDN N/A
- MMI N/A
- Industry
- VRDN Medical Specialities
- MMI Real Estate
- Sector
- VRDN Health Care
- MMI Finance
- Exchange
- VRDN Nasdaq
- MMI Nasdaq
- Market Cap
- VRDN 1.6B
- MMI 1.3B
- IPO Year
- VRDN N/A
- MMI 2013
- Fundamental
- Price
- VRDN $13.13
- MMI $31.25
- Analyst Decision
- VRDN Buy
- MMI Sell
- Analyst Count
- VRDN 12
- MMI 1
- Target Price
- VRDN $36.44
- MMI $30.00
- AVG Volume (30 Days)
- VRDN 1.2M
- MMI 143.3K
- Earning Date
- VRDN 05-07-2025
- MMI 05-07-2025
- Dividend Yield
- VRDN N/A
- MMI 1.60%
- EPS Growth
- VRDN N/A
- MMI N/A
- EPS
- VRDN N/A
- MMI N/A
- Revenue
- VRDN $302,000.00
- MMI $696,060,000.00
- Revenue This Year
- VRDN N/A
- MMI $11.69
- Revenue Next Year
- VRDN $20,553.29
- MMI $24.07
- P/E Ratio
- VRDN N/A
- MMI N/A
- Revenue Growth
- VRDN N/A
- MMI 7.76
- 52 Week Low
- VRDN $9.90
- MMI $29.36
- 52 Week High
- VRDN $27.20
- MMI $42.80
- Technical
- Relative Strength Index (RSI)
- VRDN 46.75
- MMI 38.55
- Support Level
- VRDN $9.90
- MMI $30.62
- Resistance Level
- VRDN $14.22
- MMI $32.00
- Average True Range (ATR)
- VRDN 1.17
- MMI 1.35
- MACD
- VRDN 0.18
- MMI -0.02
- Stochastic Oscillator
- VRDN 74.77
- MMI 32.25
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.